Roivant Sciences

ROIV · NASDAQ

$34.92+$0.22 (+0.63%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $34.70

Latest news

NewsOct 5, 7:06 AM ET
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
NewsSep 23, 9:03 AM ETVandana Singh
Immunovant Ends Autoimmune Skin Disorder Program
Press releaseSep 23, 7:00 AM ETGlobe Newswire
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Press releaseSep 23, 7:00 AM ETGlobe Newswire
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
NewsSep 8, 1:13 PM ETPiero Cingari
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
NewsSep 8, 12:02 PM ETAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
NewsSep 8, 9:12 AM ETVandana Singh
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Press releaseSep 8, 6:00 AM ETGlobe Newswire
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Press releaseSep 8, 6:00 AM ETGlobe Newswire
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
Press releaseSep 6, 1:00 AM ETGlobe Newswire
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
Press releaseSep 6, 1:00 AM ETGlobe Newswire
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
NewsAug 31, 2:37 PM ETVandana Singh
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
Press releaseAug 27, 3:29 PM ETGlobe Newswire
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
NewsAug 21, 12:36 PM ETVandana Singh
Why Is Arbutus Biopharma Stock Gaining Friday?
NewsAug 14, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Press releaseJul 23, 4:05 PM ETGlobe Newswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Press releaseJul 23, 4:05 PM ETGlobe Newswire
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
NewsJun 25, 1:57 PM ETVandana Singh
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
NewsMay 20, 1:19 PM ETPiero Cingari
S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today
NewsMay 20, 12:16 PM ETAvi Kapoor
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
NewsMay 20, 10:02 AM ETAvi Kapoor
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
NewsMay 20, 9:28 AM ET
Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript
NewsMay 20, 7:11 AM ET
Earnings Scheduled For May 20, 2026
Press releaseMay 20, 7:00 AM ETGlobe Newswire
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Press releaseMay 11, 4:05 PM ETGlobe Newswire
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Press releaseMay 11, 4:05 PM ETGlobe Newswire
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
NewsApr 21, 1:58 PM ETVandana Singh
Europe Clears First Flu/COVID Combo Shot From Moderna
Press releaseApr 2, 5:00 AM ETGlobe Newswire
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Press releaseMar 3, 4:15 PM ETGlobe Newswire
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Press releaseMar 3, 4:15 PM ETGlobe Newswire
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
NewsFeb 6, 12:46 PM ETAvi Kapoor
Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings
Press releaseFeb 6, 7:00 AM ETGlobe Newswire
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Press releaseJan 23, 5:25 PM ETGlobe Newswire
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Press releaseJan 23, 4:15 PM ETGlobe Newswire
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
NewsJan 20, 10:31 AM ETVandana Singh
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call

Immunovant Ends Autoimmune Skin Disorder Program

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026

FDA Clears First Targeted Dermatomyositis Treatment From Roivant

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Why Is Arbutus Biopharma Stock Gaining Friday?

9 Health Care Stocks Whale Activity In Today’s Session

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today

Crude Oil Down 5%; Lowe's Posts Upbeat Earnings

TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday

Roivant Sciences Reports Q4 2026 Results: Full Earnings Call Transcript

Earnings Scheduled For May 20, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Europe Clears First Flu/COVID Combo Shot From Moderna

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report